Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Switching from etravirine- to doravirine-containing regimen maintains viral suppression in people with HIV-1 infection, including those with archived resistance to NNRTIs.

Patients with and without HIV had similar 1- and 3-year survival outcomes following kidney transplantation, however, 5-year survival outcomes differed significantly.

The ECDC says the region could still meet its testing targets for HIV, but that it will be harder to improve detection for ...

In the early 1980s, men and women in the prime of their lives began arriving at Walter Reed Medical Center, wrecked by a ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...